Broadfin Capital as of Dec. 31, 2018
Portfolio Holdings for Broadfin Capital
Broadfin Capital holds 47 positions in its portfolio as reported in the December 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Spdr S&p 500 Etf (SPY) | 23.0 | $175M | 700k | 249.92 | |
Tesaro | 7.5 | $57M | 767k | 74.25 | |
Iovance Biotherapeutics (IOVA) | 6.9 | $53M | 6.0M | 8.85 | |
SPDR S&P Biotech (XBI) | 6.6 | $50M | 700k | 71.75 | |
Nevro (NVRO) | 5.3 | $41M | 1.0M | 38.89 | |
Aratana Therapeutics | 3.3 | $25M | 4.1M | 6.13 | |
Global Blood Therapeutics In | 3.2 | $24M | 591k | 41.05 | |
Retrophin | 3.0 | $23M | 1.0M | 22.63 | |
Adamas Pharmaceuticals | 2.9 | $22M | 2.6M | 8.54 | |
Dex (DXCM) | 2.8 | $22M | 180k | 119.80 | |
Zogenix | 2.6 | $20M | 536k | 36.46 | |
La Jolla Pharmaceuticl Com Par | 2.4 | $18M | 1.9M | 9.43 | |
BioDelivery Sciences International | 2.1 | $16M | 4.4M | 3.70 | |
Recro Pharma | 1.9 | $15M | 2.0M | 7.10 | |
Aclaris Therapeutics (ACRS) | 1.8 | $14M | 1.9M | 7.39 | |
Strongbridge Bioph shs usd | 1.7 | $13M | 2.8M | 4.48 | |
Catalyst Pharmaceutical Partners (CPRX) | 1.6 | $12M | 6.3M | 1.92 | |
Incyte Corporation (INCY) | 1.5 | $12M | 183k | 63.59 | |
Nanostring Technologies (NSTGQ) | 1.4 | $11M | 721k | 14.83 | |
Quotient | 1.4 | $10M | 1.7M | 6.12 | |
Adma Biologics (ADMA) | 1.3 | $10M | 4.2M | 2.39 | |
Antares Pharma | 1.2 | $9.4M | 3.4M | 2.72 | |
Integra LifeSciences Holdings (IART) | 1.2 | $8.9M | 197k | 45.10 | |
Mirati Therapeutics | 1.1 | $8.5M | 200k | 42.42 | |
Intersect Ent | 1.1 | $8.1M | 288k | 28.18 | |
Flamel Technologies Sa | 1.1 | $8.0M | 3.1M | 2.58 | |
Sierra Oncology | 0.8 | $6.4M | 4.9M | 1.32 | |
Alexion Pharmaceuticals | 0.8 | $5.7M | 59k | 97.36 | |
Strata Skin Sciences | 0.7 | $5.6M | 2.2M | 2.60 | |
Viewray (VRAYQ) | 0.7 | $5.3M | 867k | 6.07 | |
Sol Gel Technologies (SLGL) | 0.7 | $5.1M | 848k | 6.02 | |
Biohaven Pharmaceutical Holding | 0.6 | $4.8M | 129k | 36.98 | |
Livanova Plc Ord (LIVN) | 0.6 | $4.7M | 51k | 91.47 | |
Optinose (OPTN) | 0.6 | $4.4M | 711k | 6.20 | |
Neos Therapeutics | 0.6 | $4.3M | 2.6M | 1.65 | |
Osmotica Pharmaceuticals (RVLPQ) | 0.5 | $4.1M | 529k | 7.75 | |
Teligent | 0.5 | $3.9M | 2.8M | 1.37 | |
Tandem Diabetes Care (TNDM) | 0.4 | $3.4M | 89k | 37.97 | |
Vericel (VCEL) | 0.4 | $3.3M | 190k | 17.40 | |
Heron Therapeutics (HRTX) | 0.4 | $3.1M | 119k | 25.94 | |
Kalvista Pharmaceuticals (KALV) | 0.4 | $2.8M | 143k | 19.75 | |
Dova Pharmaceuticals | 0.3 | $2.7M | 352k | 7.58 | |
Kala Pharmaceuticals | 0.2 | $1.7M | 339k | 4.89 | |
Eiger Biopharmaceuticals | 0.2 | $1.5M | 143k | 10.16 | |
Idera Pharmaceuticals | 0.2 | $1.3M | 487k | 2.77 | |
Alphatec Holdings (ATEC) | 0.1 | $1.0M | 450k | 2.29 | |
Noveliontherapeuti.. | 0.1 | $1.0M | 1.2M | 0.84 |